Pharmacotherapy of LAMA/LABA inhaled therapy combinations for chronic obstructive pulmonary disease: a clinical overview

References

• Cazzola M, Page C, Rogliani P, et al. Dual bronchodilation for the treatment of COPD: from bench to bedside. Br J Clin Pharmacol. 2022;88(8):3657–3673. Epub ahead of print.
   Google Scholar
• Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2022 Report). Available at: https://goldcopd.org. Last access 2022 Jun 4.
   Google Scholar
• Cazzola M, Matera MG. POINT: should LAMA/LABA combination therapy be used as initial maintenance treatment for COPD? Yes. Chest. 2018;154(4):746–748.
   Google Scholar
• Nici L, Mammen MJ, Charbek E, et al., Pharmacologic management of chronic obstructive pulmonary disease. An official American thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020 201(9): e56–e69.
   Google Scholar
• Miravitlles M, Calle M, Molina J, et al., Spanish COPD guidelines (GesEPOC) 2021: updated pharmacological treatment of stable COPD. Arch Bronconeumol. 2022;58(1):T69–T81.
   Google Scholar
• British National Institute for Health and Care Excellence (NICE). Chronic obstructive pulmonary disease in over 16s: diagnosis and management. Available at: https://www.nice.org.uk/guidance/ng115/resources/chronic-obstructive-pulmonary-disease-in-over-16s-diagnosis-and-management-pdf-66141600098245. Last access 2022 Jun 4.
   Google Scholar
• de Oca M M, López Varela MV, Acuña A, et al. Incorporating New Evidence on Inhaled Medications in COPD. The Latin American Chest Association (ALAT) 2019. Arch Bronconeumol (Engl Ed). 2020;56(2):106–113.
   Google Scholar
• Zysman M, Baptista BR, Soumagne T, et al. Position paper of the French society of respiratory diseases regarding pharmacological treatment optimization for stable COPD in 2021. Respir Med Res. 2022;81:100889.
   Google Scholar
• Bourbeau J, Bhutani M, Hernandez P, et al. Canadian thoracic society clinical practice guideline on pharmacotherapy in patients with COPD - 2019 update of evidence. Can J Respir Crit Care Sleep Med. 2019;3(4):210–232.
   Google Scholar
• Cazzola M, Matera MG. An obvious paradigm: choosing bronchodilators and inhaled corticosteroids for their pharmacologic characteristics. Chest. 2021;160(4):1157–1159.
   Google Scholar
• Calverley PMA. Guidance for the better care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(9):1022–1023.
   Google Scholar
• Alhazzani W, Guyatt G. An overview of the GRADE approach and a peek at the future. Med J Aust. 2018;209(7):291–292.
   Google Scholar
• Travers J, Marsh S, Caldwell B, et al. External validity of randomized controlled trials in COPD. Respir Med. 2007;101(6):1313–1320.
   Google Scholar
• Krishnan JA. Con: comparative effectiveness research. More than dollars and cents. Am J Respir Crit Care Med. 2011;183(8):975–976.
   Google Scholar
• Cazzola M, Segreti A, Rogliani P. Comparative effectiveness of drugs for chronic obstructive pulmonary disease. Drugs Today (Barc). 2012;48(12):785–794.
   Google Scholar
• Mularski RA, McBurnie MA, Lindenauer PK, et al. Comparative effectiveness research in chronic obstructive pulmonary disease. J Comp Eff Res. 2012;1(1):71–82.
   Google Scholar
• Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019;20(1):238.
   Google Scholar
• Vogelmeier CF, Naya IP, Maltais F, et al. Treatment of COPD with long-acting bronchodilators: association between early and longer-term clinically significant improvement. Int J Chron Obstruct Pulmon Dis. 2021;16:1215–1226.
   Google Scholar
• Bjermer L, Boucot IH, Maltais F, et al., Dual bronchodilator therapy as first-line treatment in maintenance-naïve patients with symptomatic COPD: a pre-specified analysis of the EMAX trial. Int J Chron Obstruct Pulmon Dis. 2021;28(16):1939–1956.
   Google Scholar
• Vogelmeier CF, Kerwin EM, Bjermer LH, et al. Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial. Ther Adv Respir Dis. 2020;14:1753466620968500.
   Google Scholar
• Vogelmeier CF, Jones PW, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial. Respir Res. 2021;22(1):279.
   Google Scholar
• Maltais F, Naya IP, Vogelmeier CF, et al. Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial. Respir Res. 2020;21(1):280.
   Google Scholar
• Bjermer LH, Boucot IH, Vogelmeier CF, et al. Efficacy and safety of umeclidinium/vilanterol in current and former smokers with COPD: a prespecified analysis of the EMAX trial. Adv Ther. 2021;38(9):4815–4835.
   Google Scholar
• Beaulieu J, Jensen D, O’Donnell DE, et al. Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol/glycopyrronium versus tiotropium: the RED trial. Ther Adv Respir Dis. 2020;14:1753466620939507.
   Google Scholar
• Maltais F, Aumann JL, Kirsten AM, et al. Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD. Eur Respir J. 2019;53(3):1802049.
   Google Scholar
• Lee SH, Rhee CK, Yoo K, et al. Direct switch from tiotropium to indacaterol/glycopyrronium in chronic obstructive pulmonary disease patients in Korea. Tuberc Respir Dis (Seoul). 2021;84(2):96–104.
   Google Scholar
• Kardos P, Hagedorn-Peinz I. The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study - the FAVOR study. Int J Chron Obstruct Pulmon Dis. 2017;13:69–77.
   Google Scholar
• Kaplan A, Chapman KR, Anees SM, et al. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study. Int J Chron Obstruct Pulmon Dis. 2019;14:249–260.
   Google Scholar
• Domnik NJ, James MD, Scheeren RE, et al., Deterioration of nighttime respiratory mechanics in COPD: impact of bronchodilator therapy. Chest. 2021;159(1):116–127.
   Google Scholar
• Watz H, Troosters T, Beeh KM, et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2545–2558.
   Google Scholar
• Koopman M, Franssen FME, Gaffron S, et al. Differential outcomes following 4 weeks of aclidinium/formoterol in patients with COPD: a reanalysis of the ACTIVATE study. Int J Chron Obstruct Pulmon Dis. 2022;17:517–533.
   Google Scholar
• Requena G, Banks V, Czira A, et al. Characteristics and treatment pathways of patients with COPD receiving a long-acting muscarinic antagonist/long-acting β2-agonist (LABA/LAMA) in the UK. Eur Respir J. 2021;58:A2403.
   Google Scholar
• Cheng W, Duan J, Zhou A, et al. Real-world effectiveness of inhalation therapy among patients with symptomatic COPD in China: a multicenter prospective study. Front Pharmacol. 2021;12:753653.
   Google Scholar
• Jo YS, Park HY. Impact of LAMA/LABA on reducing exacerbation in patients with GOLD A or B COPD [abstract]. Chest. 2021;160(4 suppl):A1865.
   Google Scholar
• Shin H, Kim T, Kwon Y. Mono-bronchodilator therapy versus dual bronchodilator therapy in symptomatic COPD patients: the Korea COPD Subgroup Study Team cohort [abstract]. Am J Respir Crit Care Med. 2022;205:A2790.
   Google Scholar
• Feldman W, Avorn J, Kesselheim A, et al. COPD exacerbations and pneumonia hospitalizations in new users of combination maintenance inhalers: a comparative effectiveness and safety study [abstract]. Chest. 2021;160(4):A1795.
   Google Scholar
• Monteagudo M, Nuñez A, Barrecheguren M, et al. Effectiveness of treatment with dual bronchodilation (LABA/LAMA) compared with combination therapy (LABA/ICS) for patients with COPD: a population-based study. Arch Bronconeumol. 2022;58(10):699–707. Epub ahead of print.
   Google Scholar
• Wang MT, Lai JH, Huang YL, et al., Comparative effectiveness and safety of different types of inhaled long-acting β2 agonist plus inhaled long-acting muscarinic antagonist vs inhaled long-acting β2 agonist plus inhaled corticosteroid fixed-dose combinations in COPD. A propensity score-inverse probability of treatment weighting cohort study. Chest. 2021;160(4):1255–1270.
   Google Scholar
• Quint JK, Montonen J, Esposito DB, et al. Effectiveness and safety of COPD maintenance therapy with tiotropium/olodaterol versus LABA/ICS in a US claims database. Adv Ther. 2021;38(5):2249–2270.
   Google Scholar
• Jayanthi N, Krishnan K, Sudhir M, et al. Comparative study on the effectiveness of glycopyrrolate/formoterol versus tiotropium/formoterol in patients with chronic obstructive pulmonary disease. Contemp Clin Trials Commun. 2022;28:100931.
   Google Scholar
• Muraki M, Kunita Y, Shirahase K, et al. A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease. BMC Pulm Med. 2021;21(1):26.
   Google Scholar
• Gong Y, Lv Y, Liu H, et al. Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD. Ther Adv Respir Dis. 2022;16:17534666211066068.
   Google Scholar
• Cheng SL. Comparison of effectiveness using different dual bronchodilator agents in chronic obstructive pulmonary disease treatment. J Clin Med. 2021;10(12):2649.
   Google Scholar
• Hsieh MJ, Chen NH, Cheng SL, et al. Comparing clinical outcomes of tiotropium/olodaterol, umeclidinium/vilanterol, and indacaterol/glycopyrronium fixed-dose combination therapy in patients with chronic obstructive pulmonary disease in Taiwan: a multicenter cohort study. Int J Chron Obstruct Pulmon Dis. 2022;17:967–976.
   Google Scholar
• Ismaila AS, Haeussler K, Czira A, et al. Comparative efficacy of umeclidinium/vilanterol versus other bronchodilators for the treatment of chronic obstructive pulmonary disease: a network meta-analysis. Adv Ther. 2022. DOI: 10.1007/s12325-022-02234-x. Epub ahead of print.
   Google Scholar
• Watz H. On trapped air and trapped blood in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2019;199(9):1047–1048.
   Google Scholar
• Roche N, Chapman KR, Vogelmeier CF, et al. Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. data from the FLAME trial. Am J Respir Crit Care Med. 2017;195(9):1189–1197.
   Google Scholar
• Cazzola M, Matera MG. Combining dual bronchodilation and β-blockade in patients with an overlap between COPD and cardiovascular diseases. Chest. 2018;153(6):1289–1291.
   Google Scholar
• Parkin L, Williams S, Barson D, et al. Is the use of two versus one long-acting bronchodilator by patients with COPD associated with a higher risk of acute coronary syndrome in real-world clinical practice? BMJ Open Respir Res. 2021;8(1):e000840.
   Google Scholar
• Parkin L, Williams S, Sharples K, et al. Dual versus single long-acting bronchodilator use could raise acute coronary syndrome risk by over 50%: a population-based nested case-control study. J Intern Med. 2021;290(5):1028–1038.
   Google Scholar
• Almagro P, Malik K, Martínez-Camblor PR. Dual versus single long-acting bronchodilator use could raise acute coronary syndrome risk by over 50%. J Intern Med. 2022;291(5):705–706.
   Google Scholar
• Cazzola M, Rogliani P, Laitano R, et al. Beyond dual bronchodilation - triple therapy, when and why. Int J Chron Obstruct Pulmon Dis. 2022;17:165–180.
   Google Scholar
• Miravitlles M, Verhamme K, Calverley PMA, et al. A pooled analysis of mortality in patients with COPD receiving dual bronchodilation with and without additional inhaled corticosteroid. Int J Chron Obstruct Pulmon Dis. 2022;17:545–558.
   Google Scholar
• Long H, Xu H, Janssens JP, et al. Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials. Respir Res. 2021;22(1):209.
   Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Triple inhaler versus dual bronchodilator therapy in COPD: real-world effectiveness on mortality. COPD. 2022;19(1):1–9.
   Google Scholar
• Quint JK, Montonen J, He X, et al. Effectiveness of COPD maintenance therapy with a LAMA/LABA versus LAMA/LABA/inhaled corticosteroids in a US claims database [abstract]. Chest. 2021;160(4 suppl):A1863–A1864.
   Google Scholar
• Vogelmeier C, Worth H, Buhl R, et al. Stepping down from triple inhaled therapy to a LABA/LAMA fixed-dose combination: data from the German real-life DACCORD COPD cohort [abstract]. Am J Respir Crit Care Med. 2022;205:A4775.
   Google Scholar
• Rogliani P, Ritondo BL, Gabriele M, et al. Optimizing de-escalation of inhaled corticosteroids in COPD: a systematic review of real-world findings. Expert Rev Clin Pharmacol. 2020;13(9):977–990.
   Google Scholar
• Sim M, Yii A, Xu X, et al. Characteristics of patients with the chronic obstructive pulmonary disease treated with long-acting bronchodilators in a real-world setting in Singapore: a single-center observational study. Int J Chron Obstruct Pulmon Dis. 2022;17:1349–1363.
   Google Scholar
• Hoogendoorn M, Corro Ramos I, Soulard S, et al. Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden, and the Netherlands: a model-based study. BMJ Open. 2021;11(8):e049675.
   Google Scholar
• Gong Y, Lin C, Jin Y, et al. The efficacy and cost-effectiveness of umeclidinium/vilanterol versus tiotropium in symptomatic patients with chronic obstructive pulmonary disease. Can Respir J. 2022;2022:2878648.
   Google Scholar
• Slade D, Ray R, Moretz C, et al. Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study. BMC Pulm Med. 2021;21(1):253.
   Google Scholar
• Sethi S, Palli S, Bengtson L, et al. Resource use, costs and clinical outcomes among COPD patients who initiate therapy with tiotropium/olodaterol or fluticasone furoate/umeclidinium/vilanterol. Am J Respir Crit Care Med. 2022;205:A4854.
   Google Scholar
• Cazzola M, Rogliani P, Stolz D, et al. Pharmacological treatment and current controversies in COPD. F1000Res. 2019 Faculty Rev-1533;8:F1000.
   Google Scholar
• Cazzola M, Segreti A, Stirpe E, et al. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. Respir Med. 2013;107(1):107–111.
   Google Scholar
• Matera MG, Rogliani P, Calzetta L, et al. Safety considerations with dual bronchodilator therapy in COPD: an update. Drug Saf. 2016;39(6):501–508.
   Google Scholar
• Wang MT, Liou JT, Lin CW, et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern Med. 2018;178(2):229–238.
   Google Scholar
• Cazzola M, Matera MG, Rogliani P, et al. Comparative studies of dual bronchodilation in COPD. Monaldi Arch Chest Dis. 2021;91(1). DOI: 10.4081/monaldi.2021.1625.
   Google Scholar